Bionomics Ltd
ASX:BNO
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Johnson & Johnson
NYSE:JNJ
|
US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
US |
|
Bank of America Corp
NYSE:BAC
|
US |
|
Mastercard Inc
NYSE:MA
|
US |
|
UnitedHealth Group Inc
NYSE:UNH
|
US |
|
Exxon Mobil Corp
NYSE:XOM
|
US |
|
Pfizer Inc
NYSE:PFE
|
US |
|
Nike Inc
NYSE:NKE
|
US |
|
Visa Inc
NYSE:V
|
US |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
CN |
|
JPMorgan Chase & Co
NYSE:JPM
|
US |
|
Coca-Cola Co
NYSE:KO
|
US |
|
Verizon Communications Inc
NYSE:VZ
|
US |
|
Chevron Corp
NYSE:CVX
|
US |
|
Walt Disney Co
NYSE:DIS
|
US |
|
PayPal Holdings Inc
NASDAQ:PYPL
|
US |
Bionomics Ltd
Other Current Liabilities
Bionomics Ltd
Other Current Liabilities Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Other Current Liabilities | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
|
Bionomics Ltd
ASX:BNO
|
Other Current Liabilities
AU$404.6k
|
CAGR 3-Years
-59%
|
CAGR 5-Years
-25%
|
CAGR 10-Years
-8%
|
|
|
Mesoblast Ltd
ASX:MSB
|
Other Current Liabilities
$21m
|
CAGR 3-Years
4%
|
CAGR 5-Years
3%
|
CAGR 10-Years
2%
|
|
|
CSL Ltd
ASX:CSL
|
Other Current Liabilities
$720m
|
CAGR 3-Years
9%
|
CAGR 5-Years
4%
|
CAGR 10-Years
12%
|
|
|
Chimeric Therapeutics Ltd
ASX:CHM
|
Other Current Liabilities
AU$2.5m
|
CAGR 3-Years
0%
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
Telix Pharmaceuticals Ltd
ASX:TLX
|
Other Current Liabilities
AU$89.3m
|
CAGR 3-Years
35%
|
CAGR 5-Years
47%
|
CAGR 10-Years
N/A
|
|
|
PYC Therapeutics Ltd
ASX:PYC
|
Other Current Liabilities
N/A
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
Bionomics Ltd
Glance View
Bionomics Ltd. is a clinical stage biopharmaceutical company. The firm is engaged in discovery and development of novel drug candidates focused on the treatment of central nervous system disorders. The firm's segment includes Drug discovery and development and Contract services. Drug discovery and development segment includes discovery, development, and commercialization of compounds to match a target product profile. Contract services segment includes provision of scientific services on a fee for service basis to both external and internal customers. Its product candidates include BNC210, BNC375, BNC101 and BNC105. The BNC210 provides treatment for anxiety disorders, co-morbid anxiety, and depression. The BNC375 is a molecule therapeutics for the treatment of cognitive impairment in Alzheimer's disease (AD).The Company operates in three geographical areas, such as Australia, France and United States of America.
See Also
What is Bionomics Ltd's Other Current Liabilities?
Other Current Liabilities
404.6k
AUD
Based on the financial report for Dec 31, 2022, Bionomics Ltd's Other Current Liabilities amounts to 404.6k AUD.
What is Bionomics Ltd's Other Current Liabilities growth rate?
Other Current Liabilities CAGR 10Y
-8%
Over the last year, the Other Current Liabilities growth was 0%. The average annual Other Current Liabilities growth rates for Bionomics Ltd have been -59% over the past three years , -25% over the past five years , and -8% over the past ten years .
